Suzhou, China

Jianqing Xu


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Innovations by Jianqing Xu in Immunogenic Compositions

Introduction

Jianqing Xu is a prominent inventor based in Suzhou, China. He has made significant contributions to the field of immunology, particularly in the development of recombinant viral vectors and immunogenic compositions. With a total of 3 patents, his work focuses on enhancing vaccine efficacy and overcoming immune tolerance.

Latest Patents

Jianqing Xu's latest patents include innovative technologies that aim to improve cellular immune responses. One of his notable inventions is a recombinant viral vector that comprises a polynucleotide encoding a fusion peptide of CD4 helper T cell epitopes. This epitope fusion peptide includes cytomegalovirus and influenza virus epitopes. The recombinant viral vector and the associated immunogenic composition can significantly enhance the immune response to weak immunogens, particularly tumor antigens or infection-related antigens. Another patent involves fusion peptides of CD4 helper T cell epitopes, which also aim to improve the immune response and vaccine efficacy.

Career Highlights

Jianqing Xu is currently associated with Vacdiagn Biotechnology Co., Ltd., where he continues to innovate in the field of biotechnology. His work is instrumental in developing new strategies for vaccine enhancement and immune response modulation.

Collaborations

Jianqing Xu collaborates with notable colleagues such as Yang Huang and Xiaoyan Zhang, contributing to a dynamic research environment that fosters innovation.

Conclusion

Jianqing Xu's contributions to immunology through his patents and work at Vacdiagn Biotechnology Co., Ltd. highlight his commitment to advancing vaccine technology and improving immune responses. His innovative approaches are paving the way for more effective immunogenic compositions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…